Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia

Current Medical Research and Opinion

Volumn 29, Issue 3, 2013, Pages 241-250

  Gonzalez, Domingo ^a   Bienroth, Markus ^b   Curtis, Vivienne ^c   Debenham, Matthew ^d   Jones, Stuart ^e   Pitsi, Didier ^f   George, Mohan ^g  

^a Assertive Outreach Team   (United Kingdom)

^b OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

^e St Davids Hospital   (United Kingdom)

^f BRISTOL MYERS SQUIBB   (United States)

^g National Centre for Mental Health   (United Kingdom)

Author keywords

Agitation; Aripiprazole; Bipolar disorder; Pharmacotherapy; Rapid tranquillisation; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; PLACEBO; PROMETHAZINE;

AGITATION; BIPOLAR I DISORDER; BIPOLAR MANIA; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; RECURRENT DISEASE; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; HALOPERIDOL; HUMANS; HYPNOTICS AND SEDATIVES; PIPERAZINES; PSYCHOMOTOR AGITATION; QUINOLONES; SCHIZOPHRENIA; TRANQUILIZING AGENTS;

EID: 84873643772     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.766591     Document Type: Review

References (40)

1. Muller-Oerlinghausen B, Berghofer A, Bauer M. Bipolar disorder. Lancet 2002;359:241-7
2. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346-88
3. Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry 2011;68:241-51
4. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010;71:1115-24
5. APA. Practice Guidelines for the Treatment of Patients with Schizophrenia, Second Edition. Am J Psychiatry 2004;161:1-56
6. Harvey PD. Defining and achieving recovery from bipolar disorder. J Clin Psychiatry 2006;67(Suppl 9):14-18; discussion 36-42
7. Cañ as F. Management of agitation in the acute psychotic patient-efficacy without excessive sedation. Eur Neuropsychopharmacol 2007;17:S108-14
8. Pereira S, Clinton C. National minimum standards for general adult services in psychiatric intensive care units (PICU) and low secure environments. Mental Health Policy Implementation Guide. London: UK Department of Health, 2002
9. Taylor D, Paton C, Kapur S, eds. The Maudsley Prescribing Guidelines in Psychiatry, 11th edn. London: Wiley-Blackwell, 2012
10. Allen MH, Currier GW, Carpenter D, et al. Introduction: methods, commentary, summary. J Psychiatr Pract 2005;11(S1):5-25
11. NICE. CG25 Violence: The Short-Term Management of Disturbed/Violent Behaviour in In-patient Psychiatric Settings and Emergency Departments. 2005
12. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11:225-55
13. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005;6:132-91
14. Foster S, Kessel J, Berman ME, et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997;12:175-9
15. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335-40
16. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21(2 Suppl):106-15S
17. Yatham LN. Atypical antipsychotics for bipolar disorder. Psychiatr Clin North Am 2005;28:325-47
18. Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo-and haloperidol-controlled study. Br J Psychiatry 2009;194:40-8
19. Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophrenia Res 2006;85:222-31
20. Pretorius JL, Phillips M, Langley RW, et al. Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects. Br J Clin Pharmacol 2001;52:322-6
21. Janssen Pharmaceuticals I. Haloperidol Prescribing Information. 2009. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/ 015923s078,018701s053lbl.pdf [Last accessed August 2012]
22. Eli Lilly. Zyprexa (olanzapine) Prescribing Information. 2011, last accessed June 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2009/020592s051,021086s030,021253s036lbl.pdf
23. Boulton DW, Kollia G, Mallikaarjun S, et al. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinetics 2008;47:475-85
24. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a highaffinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9
25. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology 2002;441:137-40
26. Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483:45-53
27. Bristol-Myers Squibb. Abilify prescribing information. 2011. Available at: http://packageinserts.bms.com/pi/pi-abilify.pdf [Last accessed September 2011]
28. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;18:251-67
29. Stahl SM. Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Prim Care Comp for CNS Disorders 2003;5(Suppl 3):9-13
30. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51
31. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-8
32. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-97
33. Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, doubleblind, placebo-controlled trial. J Clin Psychiatry 2007;68:111-19
34. Andrezina R, Josiassen R, Marcus R, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with IM haloperidol. Psychopharmacology 2006;188:281-92
35. Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007;27:171-6
36. Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003; 21:192-8
37. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psych 2007;68:1876-85
38. Andrezina R, Josiassen R, Marcus R, et al. Intramuscular aripiprazole or haloperidol for the treatment of acute agitation associated with schizophrenia: sub-analysis of a double-blind, placebo-controlled study. Curr Med Res Opin 2006;22:2209-19
39. Carlson B, Ketter T, Sun W, et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord 2012;14:41-53
40. Vieta E, Owen R, Baudelet C, et al. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010;26:1485-96